Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
PDF) Discovery and Optimization of Imidazopyridine-based
Full article: Patent landscape for discovery of promising
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Beyond triglyceride synthesis: the dynamic functional roles of
US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the
NASH Target Development Service for DAG O-Acyltransferase (DGAT
Frontiers New insights into the role of dietary triglyceride
BMS-963272Cas# 1441057-15-3
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Non-Alcoholic Steatohepatitis disease: Malacards - Research
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
de
por adulto (o preço varia de acordo com o tamanho do grupo)
